Patents by Inventor Sandra Steiner
Sandra Steiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11840528Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: December 11, 2020Date of Patent: December 12, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
-
Patent number: 11708354Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: November 24, 2020Date of Patent: July 25, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20230054473Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315577Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and R10 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315593Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315592Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315591Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220135571Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 21, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
-
Publication number: 20220112199Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11117890Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 2, 2019Date of Patent: September 14, 2021Assignee: Hoffman La-Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20210094945Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 11, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
-
Publication number: 20210079005Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20210070739Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 24, 2020Publication date: March 11, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 10882848Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: June 21, 2019Date of Patent: January 5, 2021Assignee: Hoffmann-La Roche, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200361930Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200308171Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Georg Jaeschke, Bernd Kuhn, Antonio Ricci, Daniel Rueher, Sandra Steiner, Yvonne Alice Nagel, Martin Duplessis, Kiel Lazarski, Yanke Liang
-
Patent number: 10730881Abstract: The present invention relates to a compound of formula I wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, —CH2—C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower alkyl substituted by halogen; R2 is a five or six membered heteroaryl group, selected from wherein R6 is hydrogen, lower alkyl, halogen or lower alkoxy; and R7 is hydrogen, lower alkoxy or halogen; R3 is lower alkyl or lower alkyl substituted by hydroxy: R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; n is 1 or 2; -( )n- is —CH2— or —CH2CH2— for n being 1 or 2; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndromType: GrantFiled: January 10, 2019Date of Patent: August 4, 2020Assignee: HOFFMANN-LA ROCHE, INC.Inventors: Bjoern Bartels, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Sandra Steiner
-
Patent number: 10669276Abstract: The present invention relates to compounds of formula I, wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, —CH2—C3-6-cycloalkyl, or bridged C3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halogen, lower alkyl or lower alkyl substituted by halogen; R2 is hydrogen, halogen, lower alkoxy, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R3 is a five membered heteroaryl group, selected from wherein R6 is hydrogen or lower alkyl; R7 is halogen or lower alkyl; R8 is hydrogen or lower alkyl; R9 is hydrogen or lower alkyl; R4 is lower alkyl or lower alkyl substituted by hydroxy; R5/R5? is independently from each other hydrogen or lower alkyl; -( )n- is —CH2— or —CH2CH2— for n being 1 or 2; X is CH or N; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof.Type: GrantFiled: December 21, 2018Date of Patent: June 2, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Bjoern Bartels, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Hasane Ratni, Sandra Steiner, Michael Reutlinger
-
Publication number: 20200102299Abstract: The present invention provides compounds which are selective allosteric inhibitors of TMLR, TMLRCS, LR, LACS containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: December 2, 2019Publication date: April 2, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20190308955Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: June 21, 2019Publication date: October 10, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner